GSK plc Stock Nyse

Equities

GSK

US37733W2044

Pharmaceuticals

Market Closed - Nyse 16:00:02 2024-04-26 EDT Pre-market 08:27:35
41.11 USD +0.49% Intraday chart for GSK plc 41.75 +1.56%

Financials

Sales 2024 * 31.48B 39.48B 53.9B Sales 2025 * 33.38B 41.87B 57.16B Capitalization 67.54B 84.72B 116B
Net income 2024 * 5.66B 7.1B 9.7B Net income 2025 * 6.4B 8.02B 10.95B EV / Sales 2024 * 2.53 x
Net Debt 2024 * 12.17B 15.26B 20.83B Net Debt 2025 * 8.93B 11.2B 15.29B EV / Sales 2025 * 2.29 x
P/E ratio 2024 *
11.9 x
P/E ratio 2025 *
10.6 x
Employees 70,212
Yield 2024 *
3.68%
Yield 2025 *
3.92%
Free-Float 92.52%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.56%
1 week+3.42%
Current month-4.11%
1 month-4.11%
3 months+5.22%
6 months+18.95%
Current year+10.93%
More quotes
1 week
40.60
Extreme 40.6
41.31
1 month
39.16
Extreme 39.155
42.87
Current year
36.82
Extreme 36.82
43.84
1 year
33.33
Extreme 33.33
43.84
3 years
28.47
Extreme 28.465
58.71
5 years
28.47
Extreme 28.465
60.31
10 years
28.47
Extreme 28.465
69.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 10-04-30
Director of Finance/CFO 62 23-04-30
Compliance Officer - 95-07-31
Members of the board TitleAgeSince
Director of Finance/CFO 62 23-04-30
Chairman 66 19-08-31
Director/Board Member 65 14-12-31
More insiders
Name Weight AuM 1st Jan change Investor Rating
2.24% 6 M€ +16.84% -
1.51% 9 M€ -4.31% -
More ETFs positioned on GSK plc
Date Price Change Volume
24-04-26 41.11 +0.49% 2,730,464
24-04-25 40.91 +0.12% 3,461,979
24-04-24 40.86 -0.92% 1,816,111
24-04-23 41.24 +1.60% 2,289,896
24-04-22 40.59 +2.11% 3,800,880

Delayed Quote Nyse, April 26, 2024 at 04:00 pm

More quotes
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.53 GBP
Average target price
20.06 GBP
Spread / Average Target
+21.34%
Consensus